Oncology

Genialis and Inventia to enhance pancreatic cancer treatment testing

Genialis has teamed up with Inventia Life Science to enhance the testing of pancreatic cancer treatments and match them to the patients who are likely to benefit.

Boehringer and Envisagenics to develop precision cancer therapies

Boehringer Ingelheim and Envisagenics have entered a research collaboration and option agreement that aims to validate tumour-specific targets for the development of precision therapies in solid tumours.

Telix to acquire ITM in deal worth up to $2.35bn

Australia-based Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich in a transaction valued at up to $2.35bn, combining Telix’s operations with ITM’s radioisotope production business and late-stage treatment candidate ITM-11.

Ona Therapeutics to develop ADC with WuXi’s payload-linker platform

WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.

FDA reduces monitoring time for Amgen’s Imdelltra infusions

The US Food and Drug Administration (FDA) has approved an update to the prescribing information for Amgen’s Imdelltra (tarlatamab-dlle), reducing the recommended monitoring time for patients with extensive-stage small cell lung cancer (ES-SCLC) after their first two infusions.

Solstice Oncology secures $225m to drive porustobart’s development for cancer

Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.

FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer

The US Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca’s Etcamah (camizestrant), used with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib), for breast cancer.

PharmaEssentia’s Besremi receives FDA approval for ET

The US Food and Drug Administration (FDA) has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).

Kazia closes oversubscribed offering to fund paxalisib’s clinical development

Kazia Therapeutics has closed an oversubscribed public offering that could provide the company with up to $120m in gross proceeds if all milestone-linked warrants are exercised, aimed primarily at funding clinical development of paxalisib.